Because malignant tumours use normal cellular mechanisms of vascularisation for growth function, oncologists have recently begun to explore angiogenesis as a valid therapeutic target. AGM-1470 [TNP-470; TAP Holdings] is an experimental first-generation anti-angiogenic agent that has been shown to potentiate standard anticancer therapiesin vivo. Although more potent angiogenesis inhibitors are now emerging, AGM-1470 is the furthest in development and the first to be testedin vivowith standard anticancer agents. The most recent animal trials combining AGM-1470 with standard antineoplastic drugs were described at the Chemotherapy Foundation Symposium XV [New York, US; November 1997].